Commenter Arne asked how we would transition from today’s healthcare system to a Single Payer format. I do not have the answer immediately at hand. I have to look for it. I do want to review what we have learned to date and stated on Angry Bear already. I do have a number of posts […]
This article by Dr. Adam Fein is drawn from the Drug Channels Institute. I can not say any of my knowledge is found in the detail of this recital. To summarize a bit as you read the detail, increases in rebates are associated with increases in list prices. Insurance coverage, the sale of drugs to […]
Medicare is almost $200 billion in gross drug spend: Who gets the blame? — 46brooklyn Research This is a complex issue as there are many moving parts to drug pricing and their costs. Perplexing in describing the drug spend issues would seem appropriate. I am not even sure if this long post will adequately define […]
“What the Inflation Reduction Act means for PBMs” Times of News This is a strange little article trying to fill a gap in knowledge. The italicized sentences are mine. It does make some sound points on PBMs so I kept it. If you can get into Seeking Alpha or Modern Healthcare, you may find a […]
Inflation Reduction Act The Inflation Reduction Act drug price negotiation is small in returns, low in the number of drugs initially impacted, and slow to start. Ten drugs will be selected and the impact of the act begins in 2026. It rises to 20 drugs to be negotiated in 2029. The new act ignores European […]
“The Justice Department moved on Thursday to block a bankruptcy plan that grants broad legal immunity to the pharmaceutical company Purdue Pharma, whose drug OxyContin has been at the heart of the nation’s opioid epidemic. William K. Harrington, the U.S. trustee for the Justice Department, filed a motion in federal court to halt confirmation of […]
Guest Author at Angry Bear is Professor Joel Eissenberg. Dr. Joel Eissenberg is a professor of Biochemistry and Molecular Biology and is probably a good source to ask questions concerning pandemics and bringing new vaccines to market. Ask questions . . . I am sure he will answer the same as he has commented in […]